1 |
Sacco R, Ramai D, Tortora R, di Costanzo GG, Burlone ME, Pirisi M, Federico P, Daniele B, Silletta M, Gallo P, Cocuzza C, Russello M, Cabibbo G, Rancatore G, Cesario S, Masi G, Marzi L, Mega A, Granito A, Pieri G, Giannini EG, Paolillo R, Gadaleta-Caldarola G, Dadduzio V, Giordano G, Giacomelli L, Papa S, Renzulli M, Maida M, Ghidini M, Borzio M, Facciorusso A; A.I.G.O. (Italian Association of Hospital Gastroenterologists). Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis. Cancers (Basel) 2023;15. [PMID: 36672330 DOI: 10.3390/cancers15020381] [Reference Citation Analysis]
|
2 |
Chen P, Li Y, Wei P, Liang L, Li B, Cao Y, Han X, Wang Y, Duan X, Jia H, Zhao T, Ren J. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma. Int Immunopharmacol 2022;111:109127. [PMID: 35964407 DOI: 10.1016/j.intimp.2022.109127] [Reference Citation Analysis]
|